112 related articles for article (PubMed ID: 3345574)
1. Hemoglobin-catalyzed transformation of elliptinium acetate into electrophilic species. Evidences for oxidative activation of the drug in human red blood cells.
Ha T; Bernadou J; Voisin E; Auclair C; Meunier B
Chem Biol Interact; 1988; 65(1):73-84. PubMed ID: 3345574
[TBL] [Abstract][Full Text] [Related]
2. Peroxidase-catalyzed covalent binding of the antitumor drug N2-methyl-9-hydroxyellipticinium to DNA in vitro.
Auclair C; Dugué B; Meunier B; Paoletti C
Biochemistry; 1986 Mar; 25(6):1240-5. PubMed ID: 3964674
[TBL] [Abstract][Full Text] [Related]
3. Peroxidase-catalysed oxidation of N2,N6-dimethyl-9-hydroxyellipticinium acetate. Evidence for the formation of an electrophilic quinone-iminium derivative.
Meunier G; Bernadou J; Meunier B
Biochem Pharmacol; 1987 Aug; 36(16):2599-604. PubMed ID: 3606658
[TBL] [Abstract][Full Text] [Related]
4. Covalent binding of elliptinium acetate (NSC 264137) to nucleic acids of L1210 cells in culture.
Dugue B; Auclair C; Meunier B
Cancer Res; 1986 Aug; 46(8):3828-33. PubMed ID: 2425935
[TBL] [Abstract][Full Text] [Related]
5. Identification of the glucuronide and glutathione conjugates of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate (Celiptium). Comparative disposition of this drug with its olivacinium isomer in rat bile.
Maftouh M; Monsarrat B; Rao RC; Meunier B; Paoletti C
Drug Metab Dispos; 1984; 12(1):111-9. PubMed ID: 6141901
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of the anti-tumour drugs N2-methyl-9-hydroxyellipticinium acetate (NSC 264137) and N2-methyl-9-hydroxyolivacinium acetate in the rat: preliminary identification of biliary 9-(O)-glucuronide and 10-(S)-glutathione conjugates.
Maftouh M; Meunier G; Dugue B; Monsarrat B; Meunier B; Paoletti C
Xenobiotica; 1983 May; 13(5):303-10. PubMed ID: 6636827
[TBL] [Abstract][Full Text] [Related]
7. Evidence for electrophilic properties of N2-methyl-9-hydroxy ellipticinium acetate (Celiptium) from human biliary metabolites.
Bernadou J; Monsarrat B; Roche H; Armand JP; Paoletti C; Meunier B
Cancer Chemother Pharmacol; 1985; 15(1):63-5. PubMed ID: 4006051
[TBL] [Abstract][Full Text] [Related]
8. 2-Alkenal modification of hemoglobin: Identification of a novel hemoglobin-specific alkanoic acid-histidine adduct.
Yoshitake J; Shibata T; Shimayama C; Uchida K
Redox Biol; 2019 May; 23():101115. PubMed ID: 30819615
[TBL] [Abstract][Full Text] [Related]
9. Uptake, cytofluorescence, and cytotoxicity of oxazolopyridocarbazoles (amino acid-ellipticine conjugates) in murine sarcoma cells.
Larsen AK; Paoletti J; Belehradek J; Paoletti C
Cancer Res; 1986 Oct; 46(10):5236-40. PubMed ID: 3756875
[TBL] [Abstract][Full Text] [Related]
10. omicron-Quinone formation in the biochemical oxidation of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate.
Bernadou J; Meunier G; Paoletti C; Meunier B
J Med Chem; 1983 Apr; 26(4):574-9. PubMed ID: 6834391
[TBL] [Abstract][Full Text] [Related]
11. The rat biliary and urinary metabolism of the N6-methylated derivative of elliptinium acetate, and antitumor agent.
Braham Y; Meunier G; Meunier B
Drug Metab Dispos; 1988; 16(2):316-21. PubMed ID: 2898353
[TBL] [Abstract][Full Text] [Related]
12. Potential antitumor agents: synthesis and biological properties of aliphatic amino acid 9-hydroxyellipticinium derivatives.
Auclair C; Voisin E; Banoun H; Paoletti C; Bernadou J; Meunier B
J Med Chem; 1984 Sep; 27(9):1161-6. PubMed ID: 6471070
[TBL] [Abstract][Full Text] [Related]
13. Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(t)ides. Biological activities of the resulting adducts.
Pratviel G; Bernadou J; Ha T; Meunier G; Cros S; Meunier B; Gillet B; Guittet E
J Med Chem; 1986 Aug; 29(8):1350-5. PubMed ID: 3090263
[TBL] [Abstract][Full Text] [Related]
14. Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide system.
Auclair C; Paoletti C
J Med Chem; 1981 Mar; 24(3):289-95. PubMed ID: 7265115
[TBL] [Abstract][Full Text] [Related]
15. Selective binding of elliptinium acetate onto the 3'-terminal ribose of diribonucleosides monophosphates.
Pratviel G; Bernadou J; Paoletti C; Meunier B; Gillet B; Guittet E; Lallemand JY
Biochem Biophys Res Commun; 1985 May; 128(3):1173-9. PubMed ID: 2408615
[TBL] [Abstract][Full Text] [Related]
16. [Demonstration of an oxidative biotransformation of 9-methoxyellipticine. Comparison with the case of 9-hydroxyellipticine].
Braham Y; Meunier G; Meunier B
C R Acad Sci III; 1987; 304(11):301-6. PubMed ID: 3103875
[TBL] [Abstract][Full Text] [Related]
17. A revised structure of the antitumor drug elliptinium--amino(acid) adducts.
Gouyette A; Auclair C; Paoletti C
Biochem Biophys Res Commun; 1985 Sep; 131(2):614-9. PubMed ID: 2996516
[TBL] [Abstract][Full Text] [Related]
18. Peroxidase-catalyzed O-demethylation reactions. Quinone-imine formation from 9-methoxyellipticine derivatives.
Meunier G; Meunier B
J Biol Chem; 1985 Sep; 260(19):10576-82. PubMed ID: 4030757
[TBL] [Abstract][Full Text] [Related]
19. Human and rat urinary metabolites of the antitumor drug Celiptium (N2-methyl-9-hydroxyellipticinium acetate, NSC 264137). Identification of cysteine conjugates supporting the "biooxidative alkylation" hypothesis.
Monsarrat B; Maftouh M; Meunier G; Dugué B; Bernadou J; Armand JP; Picard-Fraire C; Meunier B; Paoletti C
Biochem Pharmacol; 1983 Dec; 32(24):3887-90. PubMed ID: 6661266
[No Abstract] [Full Text] [Related]
20. Regioselective arylation of ribose in adenosine and guanosine with the antitumor drug N2-methyl-9-hydroxyellipticinium acetate.
Bernadou J; Meunier B; Meunier G; Auclair C; Paoletti C
Proc Natl Acad Sci U S A; 1984 Mar; 81(5):1297-301. PubMed ID: 6584882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
